PAGE 2018, Montreux, Switzerland
A semi-mechanistic model of targeted therapy for melanoma
Authors: Dmitrii Shchelokov, Oleg Demin Jr
Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology
Authors: Tatiana Karelina, Alexander Stepanov, Oleg Demin
Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment
Authors: Etienne Pigeolet1, Konstantinos Biliouris2, Ulf Neumann3, Alexandra Urusova4, Oleg Demin4, Tatiana Karelina4
Affiliation: 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Institute for Biomedical Research, Cambridge, USA; 3Novartis Institute for Biomedical Research, Basel, Switzerland; 4InSysBio, Moscow, Russia
AAT-AD/PD Focus Meeting, Torino, Italy
In silico implementation of tauopathy transgenic mouse model
Speaker: Alexander Stepanov
ASCPT 2018, Orlando, FL, USA
PBPK modeling for therapeutic nanoparticles loaded with drug: distribution and release
Authors: Evgeny Metelkin, Oleg Demin
Translational QSP model of amyloid beta allows to predict both short and long term response of AD patients to different therapies
Authors: Tatiana Karelina1, Oleg Demin1, Oleg Demin Jr1, Timothy Nicholas2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
Multiple myeloma quantitative systems pharmacology model: development and usage for pomalidomide influence evaluation
Authors: Svetlana Rubina, Oleg Demin, Oleg Demin Jr
ACoP8, Fort Lauderdale, FL, US
Mechanistic model for the role of the microgliall cells in amyloid accumulation and its modulation by immunotherapy
Authors: Tatiana Karelina1, Alexander Stepanov1, Theresa Yuraszeck2, Dean Hickman2, Steve Wood2
Affiliation: 1InSysBio, Moscow, Russia; 2Amgen Inc., Thousand Oaks, CA, USA
Tau propagation system pharmacology model based on three-component memory-retrieval system predicts heterogeneous response to immunotherapy in brain regions
Authors: Tatiana Karelina1, Alexander Stepanov1, Timothy Nicholas2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
A Quantitative Systems Pharmacology Model of Asthma
Authors: Sergey Smirnov1, Galina Lebedeva1, Oleg Demin1, Tatiana Petukhova1, Lourdes Cucurull-Sanchez2, David Fairman2
Affiliation: 1InSysBio, Moscow, Russia; 2GSK Medicines Research Centre, Stevenage, UK
Model-based analysis of clinical assays for assessing the efficacy of vaccines against Respiratory Syncytial Virus (RSV)
Authors: Galina Lebedeva, Nikolai Pakhomov, Oleg Demin, Oleg Demin Jr
Evaluation of Potential Low-Dose Regimens of Oral Fixed-Dose Combination of Cytidine Deaminase Inhibitor E7727 with Decitabine (ASTX727-LD) to Minimize Decitabine-Mediated Neutropenia in Low-Risk MDS Subjects Using Systems Pharmacology Modeling
Authors: Antonina Nikitich1, Oleg Demin1, Oleg Demin Jr1, Aram Oganesian2
Affiliation: 1InSysBio, Moscow, Russia; 2Astex Pharmaceuticals Inc., Pleasanton, CA
7th German-Russian Week of the Young Researcher, Moscow, Russia
SbmlViewer is a visualization tool for systems biology modeling
Authors: Viktoria Tkachenko, Evgeny Metelkin
AD/PD 2017, Vienna, Austria
Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model
Authors: Tatiana Karelina1, Timothy Nicholas2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA